

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/583,342	05/31/2000	Frederic Bushman	1211.002US1	2389
21186 75	590 12/10/2002			
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.			EXAMINER	
P.O. BOX 2938 MINNEAPOLI	-		CHAKRABARTI, ARUN K	
			ART UNIT	PAPER NUMBER
			1634 DATE MAILED: 12/10/2002	In

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/583,342

Applicant(s)

1.155...

Bushman

Examiner

Arun Chakrabarti

Art Unit **1634**



		on the cover sheet with the correspondence address
Period f		
THE N	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	
	ons of time may be available under the provisions of 37 CFR 1.136 (a). In date of this communication.	no event, however, may a reply be timely filed after SIX (6) MONTHS from the
- If the po - If NO po - Failure t - Any rep	ariod for reply specified above is less than thirty (30) days, a reply within t	and will expire SIX (6) MONTHS from the mailing date of this communication. ne application to become ABANDONED (35 U.S.C. § 133).
Status	paton tom adjustment, eee or or 1.70-4bj.	
1) 💢	Responsive to communication(s) filed on Nov 18, 2	2002 .
2a) 🗶	This action is FINAL . 2b) ☐ This act	ion is non-final.
	Since this application is in condition for allowance closed in accordance with the practice under Ex pa	except for formal matters, prosecution as to the merits is re Quayle, 1935 C.D. 11; 453 O.G. 213.
Dispositi	on of Claims	
4) 💢	Claim(s) 1-16, 20, 22, and 23	is/are pending in the application.
4	a) Of the above, claim(s)	is/are withdrawn from consideration.
5) 🗆	Claim(s)	is/are allowed.
6) 💢	Claim(s) <u>1-16, 20, 22, and 23</u>	is/are rejected.
7) 🗌	Claim(s)	is/are objected to.
8) 🗌	Claims	are subject to restriction and/or election requirement.
Applicat	ion Papers	
9) 🗌	The specification is objected to by the Examiner.	
10)	The drawing(s) filed onis/are	a) \square accepted or b) \square objected to by the Examiner.
_	Applicant may not request that any objection to the d	
11) 🗆	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.
_	If approved, corrected drawings are required in reply t	o this Office action.
12)	The oath or declaration is objected to by the Exami	ner.
	under 35 U.S.C. §§ 119 and 120	
	Acknowledgement is made of a claim for foreign pr	iority under 35 U.S.C. § 119(a)-(d) or (f).
a) 🗀	All b)□ Some* c)□ None of:	
1	. Certified copies of the priority documents have	
	. Certified copies of the priority documents have	
	 Copies of the certified copies of the priority do application from the International Bures the attached detailed Office action for a list of the 	ocuments have been received in this National Stage au (PCT Rule 17.2(a)).
_		
	Acknowledgement is made of a claim for domestic The translation of the foreign language provisiona	
	Acknowledgement is made of a claim for domestic	
Attachmer		priority unual 55 0.5.0. 33 120 dilu/or 121,
	se of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
2) Notice	se of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
3) Infor	mation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) X Other: Detailed Action

Art Unit: 1634

DETAILED ACTION

Specification

1. Claims 1 and 20 have been amended and new claims 22 and 23 have been added.

Claim Rejections - 35 USC § 102

- 2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
 - (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- 3. Claims 1-16, 20, 22, and 23 are rejected under 35 U.S.C. 102 (a) as being anticipated by Lynch et al. (U.S. Patent 5,998,152) (December 7, 1999).

Lynch et al teach a high-throughput method of screening compounds capable of modulating topoisomerase activity (Abstract and Column 3, line 65 to Column 4, line 6) comprising:

- a) incubating at least a first nucleic acid, a topoisomerase and a potential topoisomerasemodulating compound, wherein the nucleic acid comprises at least one tag (Figures 1-4 and Examples 1-3 and Column 19, lines 25-32), and
 - b) assaying for nucleic acid religation product (Figures 1-4 and Column 19, line 32-60).

Lynch et al teach a high-throughput method, wherein the nucleic acid is DNA and RNA (Column 9, lines 33-47).

Page 3

Art Unit: 1634

Lynch et al teach a high-throughput method, wherein the at least one tag is a detection tag or an affinity tag (Column 2, lines 36-49 and Column 10, line 21 to Column 12, line 64).

Lynch et al teach a high-throughput method, wherein the method comprises incubating at least a first nucleic acid and a second nucleic acid ((Figures 1-4 and Examples 1-3 and Column 19, lines 25-32).

Lynch et al teach a high-throughput method, wherein the second nucleic acid is a religation strand comprising oligonucleotides operatively associated with at least one marker tag (Column 5, lines 6-67 and Figures 1-4).

Lynch et al teach a high-throughput method, wherein the first nucleic acid is operatively associated with an affinity tag and the second nucleic acid is operatively associated with a detection tag (Column 14, line 30 to column 16, line 13).

Lynch et al teach a high-throughput method, wherein the assay detects for topoisomerase inhibitors and activators (Column 1, line 13 to column 2, line 49).

Lynch et al teach a high-throughput method, wherein the topoisomerase is a Type I or Type II or Type III or Type IV isomerase (Column 5, lines 5-67).

Lynch et al teach a high-throughput method, wherein assaying comprises measuring the level of nucleic acid religation activity in the presence and absence of the topoisomerase modulating compound (Figures 1-4 and Column 19, line 25 to Column 21, line 16).

Page 4

Art Unit: 1634

Lynch et al teach a high-throughput method, wherein the level of religation activity is inversely proportional to the effectiveness of the topoisomerase-inhibitory compound (Column 20, lines 4-8).

Lynch et al teach a high-throughput method, wherein step (a) is performed on a solid support (Figures 1, 3 and Column 15, lines 38-65 and Column 17, lines 23-63).

Lynch et al teach a high-throughput method, wherein step (a) is performed in a liquid phase (Column 17, line 65 to Column 19, line 50).

Lynch et al teach a high-throughput method, wherein the nucleic acid and topoisomerase are covalently complexed, wherein the topoisomerase retains its religation activity (Column 15, lines 11-15 and Figure 1).

Lynch et al teach a kit for screening compounds that modulate topoisomerase religation activity comprising:

- a) a substrate nucleic acid comprising a first tag,
- b) a religation nucleic acid comprising a second tag and a 5'-OH,
- c) a topoisomerase, and
- d) a means for measuring a covalently linked product comprising (a) and (b) in a test mixture comprising a), b) and c) in the presence or absence of a topoisomerase modulating compound (Column 2, lines 37-52 and Column 21, lines 18-63 and Column 10, line 55 to Column 11, line 23).

Art Unit: 1634

Lynch et al teach a method to identify a compound that modulates topoisomerase activity comprising:

Page 5

- (a) incubating a reaction mixture comprising a substrate nucleic acid, a religation strand, a topoisomerase, and a candidate compound; and
- (b) assaying for intramolecular ligation of the substrate nucleic acid to form a and the religation strand to form a circular or hairpin nucleic acid (Abstract and Figures 1-4).

Response to Amendment

4. In response to amendment, 102(e) rejection has been withdrawn. However, a new 102(a) rejection has been included.

Response to Arguments

5. Applicant's arguments with respect to all pending claims have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

6. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL.** See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CAR 1.136(a).

Art Unit: 1634

Page 6

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CAR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D., whose telephone number is (703) 306-5818. The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-7401. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group analyst Chantae Dessau whose telephone number is (703) 605-1237.

Arun Chakrabarti,

Patent Examiner,

December 4, 2002

| XVI. Gary Jones Supervisory Patent Examiner Technology Center 1600